ArticleExperimental and therapeutic medicine2018
MicroRNA-133b inhibits cell proliferation and promotes apoptosis by targeting cullin 4B in esophageal squamous cell carcinoma.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Genetic variant in miR-17-92 cluster binding sites is associated with esophageal squamous cell carcinoma risk in Chinese population.BMC cancer · 2022Article
- MiR-674-5p Suppresses the Proliferation and Migration of Glioma Cells by Targeting Cul4b.Neurochemical research · 2022Article
- CUL4B is a Potential Novel Prognostic Biomarker and is Correlated with Immune Infiltrates in Malignant Pleural Mesothelioma.International journal of general medicine · 2022Article
- miRNA-425-5p enhances diffuse large B cell lymphoma growth by targeting PTEN.Translational cancer research · 2021Article
- THAP9-AS1/miR-133b/SOX4 positive feedback loop facilitates the progression of esophageal squamous cell carcinoma.Cell death & disease · 2021Article
- A positive feedback loop between AlkB homolog 5 and miR-193a-3p promotes growth and metastasis in esophageal squamous cell carcinoma.Human cell · 2021Article
- Bioinformatics-based analysis of the lncRNA-miRNA-mRNA and TF regulatory networks reveals functional genes in esophageal squamous cell carcinoma.Bioscience reports · 2020Article
- Silencing lncRNAs PVT1 Upregulates miR-145 and Confers Inhibitory Effects on Viability, Invasion, and Migration in EC.Molecular therapy. Nucleic acids · 2020Article
- Emerging Role of Non-Coding RNAs in Esophageal Squamous Cell Carcinoma.International journal of molecular sciences · 2019Review
- Down-regulation of long noncoding RNA PVT1 inhibits esophageal carcinoma cell migration and invasion and promotes cell apoptosis via microRNA-145-mediated inhibition of FSCN1.Molecular oncology · 2019Article
- MicroRNA-133b/EGFR axis regulates esophageal squamous cell carcinoma metastases by suppressing anoikis resistance and anchorage-independent growth.Cancer cell international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
microRNAs (miRs) serve a role as modulators during carcinogenesis. It has been demonstrated that the expression of miR-133b is decreased in a variety of tumor tissues and cell lines and serves a suppressive role in the proliferation and apoptosis of different types of tumor cells. However, its effect on esophageal squamous cell carcinoma (ESCC) cells remains unclear. In the current study, the expression of mature miR-133b was measured using reverse transcription-quantitative polymerase chain reaction and the results indicated that miR-133b was significantly downregulated in ESCC tissues and various ESCC cell lines. The overexpression of miR-133b significantly inhibited the proliferation and promoted the apoptosis of KYSE150 and Eca-109 cells. Furthermore, it was demonstrated that cullin 4B (CUL4B) promotes ESCC cell proliferation and inhibits apoptosis by activating the protein kinase B/glycogen synthase kinase 3β/β-catenin pathway. Taken together, these results demonstrate that miR-133b/CUL4B serves a tumor suppressive role during ESCC progression and may therefore be used as a potential target to treat patients with ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.